Proactive Investors - Run By Investors For Investors

Sativex study boosts GW Pharma

Shares in GW Pharmaceuticals received a much needed boost this morning after the Journal of Clinical Therapeutics published the results of a study which showed that Sativex(R) provided "effective long term treatment of neuropathic pain in Multiple Scherosis (MS)". The study also said that benefits of Sativex were obtained "without any evidence of tolerance to the medicine"....
no_picture_pai.jpg
Shares in GW Pharmaceuticals received a much needed boost this morning after the Journal of Clinical Therapeutics published the results of a study which showed that Sativex(R) provided "effective long term treatment of neuropathic pain in Multiple Scherosis (MS)". The study also said that benefits of Sativex were obtained "without any evidence of tolerance to the medicine".

The results of the study are a boost for GW Pharma, which despite gaining approval for the use of Sativex(R) in Canada, is still attempting to gain access to the U.S. Market. The company said that a "pivotal" Phase III trail into MS neuropathic pain had recruited 339 patients. and would the be largest clinical trial to date. Results from the Phase III trial are expected in the first half of 2008.

Salvitex(R) is produced from two key ingredients derived from the cannabis plant.

Dr Stephen Wright, GW Pharma's R&D Director added "The results add to what we know from short-term clinical trials, and we look forward to seeing the results of our ongoing pivotal study in the same condition in the first half of next year."
Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full GWP profile View Profile

GW Pharmaceuticals Timeline

Related Articles

cannabis facility
January 23 2019
The company is breaking into the large and lucrative market in the golden state
medical cannabis concept
February 10 2019
AusCann is a fully integrated early-mover pharmaceutical cannabinoid company.
1541165310_canadian-flag-1.jpg
November 02 2018
Back Home Medical Cannabis Corp has agreed on a 24,000-kilogram three-year production and supply agreement

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use